Additionally, according to Campana et al. the level of BCL2 expression influenced the sensitivity of leukemic cells to therapy because their high proliferation rate increased their susceptibility to toxic agents (21), Zhao et al. reported the similar results in NSCLC cells (22). Here, BCL2 is linked to non-small cell lung carcinoma.